| Royce A Armstrong, AUD, CCC-A | |
|
3501 S Soncy Rd, Ste 140, Amarillo, TX 79119-6407 | |
| (806) 355-5625 | |
| (806) 352-2245 |
| Full Name | Royce A Armstrong |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 18 Years |
| Location | 3501 S Soncy Rd, Amarillo, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295993210 | NPI | - | NPPES |
| 51143 | Other | TX | STATE BOARD OF EXAMINERS OF SPEECH-LANGUAGE PATHOLOGY & AUDIOLOGY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 51143 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bsa Physicians Group Inc | 3971748146 | 90 |
News Archive
Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Duke University and the University of North Carolina at Chapel Hill have been awarded funds from the National Institutes of Health to establish a prestigious Alzheimer's Disease Research Center (ADRC), part of a federally-funded national network of similar centers.
Blacks often have higher exposure to air pollution than whites, which may partially explain their higher risk heart disease and death compared to whites, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
Fever of unknown origin is characterised by a fever of more than 3 weeks' duration, temperatures of more than 38.3°C and a failure to identify the origin of the fever. Underlying causes of these fevers are difficult to diagnose, but proposed causes are infections, cancers and collagen-vascular diseases.
› Verified 3 days ago
| Provider Name | Bsa Physicians Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1457696916 PECOS PAC ID: 3971748146 Enrollment ID: O20130319000147 |
News Archive
Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Duke University and the University of North Carolina at Chapel Hill have been awarded funds from the National Institutes of Health to establish a prestigious Alzheimer's Disease Research Center (ADRC), part of a federally-funded national network of similar centers.
Blacks often have higher exposure to air pollution than whites, which may partially explain their higher risk heart disease and death compared to whites, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
Fever of unknown origin is characterised by a fever of more than 3 weeks' duration, temperatures of more than 38.3°C and a failure to identify the origin of the fever. Underlying causes of these fevers are difficult to diagnose, but proposed causes are infections, cancers and collagen-vascular diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Royce A Armstrong, AUD, CCC-A Po Box 2533, Ste 140, Amarillo, TX 79105-2533 Ph: (806) 355-5625 | Royce A Armstrong, AUD, CCC-A 3501 S Soncy Rd, Ste 140, Amarillo, TX 79119-6407 Ph: (806) 355-5625 |
News Archive
Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
Duke University and the University of North Carolina at Chapel Hill have been awarded funds from the National Institutes of Health to establish a prestigious Alzheimer's Disease Research Center (ADRC), part of a federally-funded national network of similar centers.
Blacks often have higher exposure to air pollution than whites, which may partially explain their higher risk heart disease and death compared to whites, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
Fever of unknown origin is characterised by a fever of more than 3 weeks' duration, temperatures of more than 38.3°C and a failure to identify the origin of the fever. Underlying causes of these fevers are difficult to diagnose, but proposed causes are infections, cancers and collagen-vascular diseases.
› Verified 3 days ago
Kristian Tage Ormson, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5501 W 9th Ave, Amarillo, TX 79106 Phone: 806-468-4343 Fax: 806-468-4366 | |
Physicians Hearing Center Audiologist Medicare: Not Enrolled in Medicare Practice Location: 3501 S Soncy Rd, 140, Amarillo, TX 79119 Phone: 806-352-6901 Fax: 806-352-2245 | |
Amarillo Regional Hearing And Speech Foundation Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1300 Wallace Blvd, Amarillo, TX 79106 Phone: 806-359-7681 Fax: 806-359-7755 | |
Dr. Catherine Theresa Back, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 6010 Amarillo Blvd West, Va Audiology Clinic (126), Amarillo, TX 79106 Phone: 806-355-9703 | |
Mrs. Brenda Fields Cross, AU.D., CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 720 S Tyler St, Amarillo, TX 79101 Phone: 806-651-5101 Fax: 806-651-5105 | |
Dr. Rachel Glaze, AU.D, FAAA Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1600 S Coulter St, Bldg A #105, Amarillo, TX 79106 Phone: 806-352-2321 Fax: 806-355-8941 | |
Kassidy Paige Moore, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 6830 Plum Creek Dr, Amarillo, TX 79124 Phone: 806-355-9999 Fax: 806-355-9989 |